Branches of biology

ProfNet Expert Alerts for July 10, 2020

Saturday, July 11, 2020 - 12:30am

Online Marketing & Branding Expert, Entrepreneur

Key Points: 
  • Online Marketing & Branding Expert, Entrepreneur
    "Speak from your heart, address your situation, and that will immediately attract your best and most aligned audience and potential customers.
  • In today's climate, it's as important as ever to do what we can to stay healthy and limit the spread of COVID-19.
  • Whatever a patient chooses, it is vitally important that follow-up, objective testing is done to ensure the sleep apnea is controlled.
  • His facility is also accredited by the American Academy of Dental Sleep Medicine, one of only 59 institutions nationwide to receive this distinction.

Press release - Parliament to allow COVID-19 vaccines to be developed more quickly

Saturday, July 11, 2020 - 12:04am

Parliament today adopted a new Regulation by 505 votes to 67 and 109 abstentions, via the urgent procedure, that will allow COVID-19 vaccines and treatments to be developed more quickly.

Key Points: 
  • Parliament today adopted a new Regulation by 505 votes to 67 and 109 abstentions, via the urgent procedure, that will allow COVID-19 vaccines and treatments to be developed more quickly.
  • Developing and deploying an effective and safe vaccine against the virus is the most likely permanent solution to stop the pandemic.
  • To this end, the Commission has proposed an EU vaccines strategy for COVID-19 including a temporary and strictly COVID-19-related derogation from certain rules for clinical trials.
  • Some COVID-19 vaccines and treatments already being developed may be defined genetically modified organisms (GMOs) and are thus covered by the relevant EU GMO Directives.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2020 Financial Results

Friday, July 10, 2020 - 10:41pm

OLDSMAR, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2020.

Key Points: 
  • OLDSMAR, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2020.
  • Consolidated revenues for the second quarter of fiscal 2020 were $7.87 million compared to $8.13 million for the second quarter of fiscal 2019, a 3% decrease.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.
  • Besides being AABB accredited as a cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization.

Global Cardiovascular Therapeutics Market 2020-2024 | Increasing Use of Advanced Diagnostics to Boost Growth | Technavio

Friday, July 10, 2020 - 10:30pm

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40101

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40101
    Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.
  • Our cardiovascular therapeutics market report covers the following areas:
    This study identifies the advent of novel oral anticoagulants (NOACs) as one of the prime reasons driving the cardiovascular therapeutics market growth during the next few years.
  • Backed with competitive intelligence and benchmarking, our research reports on the cardiovascular therapeutics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

Global Antibody Partnering Deals Collection 2014-2020 - Access to 1,300+ Online Deal Records; Headline, Upfront, Milestone and Royalty Data

Friday, July 10, 2020 - 6:15pm

Chapter 2 provides an overview of the trends in Antibody dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Key Points: 
  • Chapter 2 provides an overview of the trends in Antibody dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.
  • Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
  • Chapter 7 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan to 2014.

National Lipid Association Releases Official Scientific Statement on Genetic Testing in Dyslipidemia

Friday, July 10, 2020 - 5:30pm

JACKSONVILLE, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- The National Lipid Association (NLA) today announced the release of its official scientific statement on the use of genetic testing in the diagnosis and management of patients with dyslipidemia.

Key Points: 
  • JACKSONVILLE, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- The National Lipid Association (NLA) today announced the release of its official scientific statement on the use of genetic testing in the diagnosis and management of patients with dyslipidemia.
  • The statement provides insights and guidance for health care providers seeking to further their understanding of the benefits, risks and patient preferences of genetic testing.
  • The statement delves into the importance of genetic counseling before and after genetic testing and outlines potential limitations of genetic testing in dyslipidemia.
  • The manuscript, titled Genetic Testing in Dyslipidemia: A Scientific Statement from the National Lipid Association is in press with the Journal of Clinical Lipidology and can be accessed through the journal or at National Lipid Associations website at www.lipid.org.

Outlook on the Obstructive Sleep Apnea Global Market (2020 to 2024) - Develop Tactics and Strategies to Take Advantage of Opportunities - ResearchAndMarkets.com

Friday, July 10, 2020 - 5:01pm

This report provides comprehensive insights into the Obstructive Sleep Apnea pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.

Key Points: 
  • This report provides comprehensive insights into the Obstructive Sleep Apnea pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Obstructive Sleep Apnea market size and drug sales.
  • This research covers the following: Obstructive Sleep Apnea treatment options, Obstructive Sleep Apnea late stage clinical trials pipeline, Obstructive Sleep Apnea prevalence by countries, Obstructive Sleep Apnea market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Obstructive Sleep Apnea pipeline: Find out drugs in clinical trials for the treatment of Obstructive Sleep Apnea by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Obstructive Sleep Apnea drugs: Identify key drugs marketed and prescribed for Obstructive Sleep Apnea in the US, including trade name, molecule name, and company
    Obstructive Sleep Apnea drugs sales: Find out the sales value for Obstructive Sleep Apnea drugs by countries
    Obstructive Sleep Apnea market valuations: Find out the market size for Obstructive Sleep Apnea drugs in 2019 by countries.

Generex Biotechnology Announces Corporate Update and Investor Conference Call: NuGenerex Immuno-Oncology Today Friday July 10, 2020 at 4:15 PM

Friday, July 10, 2020 - 1:30pm

MIRAMAR, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for todays investor conference call on Friday July 10th 2020 at 4:15 PM Eastern time.

Key Points: 
  • MIRAMAR, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for todays investor conference call on Friday July 10th 2020 at 4:15 PM Eastern time.
  • NuGenerex Immuno-Oncology, a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines based on the CD4 T-Cell activation platform, Ii-Key.
  • Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
  • Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection (“Flesh Eating Disease”)

Friday, July 10, 2020 - 7:00am

Resolution of organ dysfunction by day 14 has been noted in the literature and was shown in this trial to have a beneficial effect on 90-day mortality.

Key Points: 
  • Resolution of organ dysfunction by day 14 has been noted in the literature and was shown in this trial to have a beneficial effect on 90-day mortality.
  • As this was the first pivotal study ever performed in NSTI, a necrotizing infection clinical composite endpoint (NICCE) was developed.
  • Successful completion of the ACCUTE trial is a major milestone for Atox Bio that reinforces our commitment to patients with NSTI.
  • NICCE included a Modified Sequential Organ Failure Assessment (mSOFA) scoring tool to evaluate resolution of organ dysfunction.

PolyU discovers the effect of chemical compound PTU on autophagy in zebrafish embryos, sheds light on cancer medication research

Friday, July 10, 2020 - 2:36am

Fast development, cost-effective and easy to breed are also primary drivers for using the zebrafish research model.

Key Points: 
  • Fast development, cost-effective and easy to breed are also primary drivers for using the zebrafish research model.
  • This ground-breaking finding subsequently sheds light on the respective research guidelines and the research protocol in on-going studies on autophagy and haematology, warranting researchers to re-examine research that is linked to existing cancer therapy options.
  • The research titled "1-phenyl 2-thiourea (PTU) Activates Autophagy in Zebrafish Embryos" ( link ) was published in Autophagy, a peer-reviewed science journal in April 2020.
  • In most research using the zebrafish model, a chemical compound called 1-phenyl-2-thiourea (PTU) is commonly used to suppress pigment formation in zebrafish embryos, maintaining optical transparency to facilitate microscopic imaging.